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The assessment of reversibility is recognized as being an essential part of the management of airways obstruction, 
but testing for reversibility of airways obstruction may not be useful for identifying patients with chronic obstructive 
pulmonary disease (COPD) who are likely to benefit from bronchodilator treatment. We studied 100 patients with 
stable COPD. Early reversibility of airways obstruction to 200 mg salbutamol and peak bronchodilation to 5Opg 
salmeterol or 200,~g salbutamol were evaluated in four different sessions (two for salbutamol and two for 
salmeterol), using a double-blind, cross-over, randomized study. Fifteen minutes after inhalation of salbutamol, 47 
patients presented an increase in FEV, greater than 15% of baseline, whereas 48 showed an increase of FEV, of at 
least 160 ml from basal value and 33 an increase in FEV, greater than both 15% of baseline and 200 ml. On the 
contrary, 69 patients presented an increase in FEV, greater than 15% of baseline, 65 an increase of FEV, of at least 
160 ml from basal value and 60 an increase in FEV, greater than both 15% of baseline and 200 ml as maximum 
increase over baseline usually 24 h after inhalation of salmeterol. Twenty-seven other subjects defined as irreversible 
by the lack of acute improvement in FEV, after salbutamol, showed an increase in FEV, greater than 15% of 
baseline, 20 showed an increase of FEV, of at least 160 ml from basal value, and 18 showed an increase in FEV, 
greater than both 15% of baseline and 200 ml; all had the maximum degree of bronchodilation usually l-2 h after 
salbutamol administration. These findings clearly demonstrate that many patients suffering from stable COPD show 
early reversibility to a short-acting &-agonist and patients who do not manifest early reversibility to salbutamol can 
still benefit from salbutamol or salmeterol. Therefore, treatments with &-agonists must always be tried. 
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Introduction 
Since most individuals with chronic obstructive pulmonary 
disease (COPD) show an increase of FEV, following inha- 
lation of a bronchodilator (l), the assessment of reversi- 
bility is recognized as being an essential part of the 
management of airways obstruction (2). In fact, the results 
of bronchodilator response tests are commonly used as a 
basis for choice of treatment by clinicians. However, the 
acute response to inhaled bronchodilators is not a repro- 
ducible guide to reversibility of airflow obstruction, and 
testing for reversibility of airways obstruction is imperfect 
in patients with COPD; in fact, it is not useful for identify- 
ing patients with chronic airway limitation who are likely to 
benefit from bronchodilator treatment (3). Moreover, the 
response is heterogeneous with different drugs (4). 
The introduction of long-acting &agonist bronchodila- 
tors gives physicians additional therapeutic options for 
COPD, but their place in COPD treatment is currently not 
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known. In any case, salmeterol appears to be more effective 
than salbutamol in patients with stable COPD (5). 
In the present study we assessed the value of early 
reversibility to salbutamol in predicting response to sal- 
meter01 in patients with stable COPD. 
Patients and Methods 
We studied 100 patients with moderate to severe COPD, 
but in a stable phase of disease, who participated in the 
study after giving their informed consent. The diagnosis of 
moderate or severe COPD was consistent with the diagnos- 
tic standards of the consensus statement of European 
Respiratory Society (ERS) (1) and established on the basis 
of clinical history, physical findings, and spirometry. All 
patients were >40 years of age, were current or previous 
smokers (> 10 pack-years) reporting dyspnoea when walk- 
ing slowly on level ground and chronic cough with sputum 
production on most days during at least 3 consecutive 
months in 2 consecutive years, who had had no change in 
symptom severity or treatment in the preceding 4 weeks, 
had shown no signs of a respiratory tract infection in the 
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TABLE 1. Early reversibility after 200,~g salbutamol (SBM) and maximum bronchodilation after 5Opg salmeterol (SLM) or 
200 pg salbutamol evaluated according to criterion 1 (a rise in FEV, of at least 15% from the baseline value), criterion 2 (an 
absolute increase in FEV, of at least 160 ml), and criterion 3 (an increase in FEV, greater than both 15% of baseline and 





Criterion 1 Criterion 2 Criterion 3 
Maximum Maximum Maximum Maximum Maximum Maximum 
increase increase 15 min increase increase 15 min increase increase 
after after after after after after after after 
SLM SBM SBM SLM SBM SBM SLM SBM 
69 74 48 65 68 33 60 51 
month preceding or during the trial, were not taking oral or 
inhaled corticosteroids for at least 3 month and had a FEV, 
~65% of predicted normal and a forced vital capacity 
(FVC) ~70% after bronchodilators had been withheld for 
24 h and had a best postbronchodilator FEV,/FVC of less 
than 0.7. Patients with a history of asthma, allergic rhinitis, 
atopy, skin-test positivity or with a total blood eosinophil 
count over 400 mm ~ 3 were excluded. Patients were also 
excluded if they had any coexisting cardiovascular or lung 
disorder. 
Early reversibility of airway obstruction to 2OOpg of 
inhaled salbutamol and peak bronchodilation to 5Opg of 
inhaled salmeterol were evaluated on 4 non-consecutive 
days (two for salbutamol and two for salmeterol), using a 
double-blind, cross-over, randomized study. Drugs were 
inhaled from a matched metered dose inhaler and holding 
chamber (AeroChamber) with mouthpiece. 
No oral bronchodilators were permitted for 1 week 
before and during the study, whereas inhaled short-acting 
bronchodilator drugs and inhaled long-acting bronchodila- 
tor agents were not permitted for at least 12 h and 24 h 
prior to each test, respectively. 
Spirometric testing was performed according to the pro- 
cedures described in the American Thoracic Society’s 1987 
update (6). Three acceptable forced expiratory manoeuvres 
were performed in order to obtain two reproducible results 
for FVC and FEV,. The highest FVC and FEV, obtained 
from one or the other of the reproducible curves, were kept 
for analysis. Measurements were performed at the follow- 
ing times: immediately before inhalation of treatment, and 
at 15, 30, 60, 120, 180, 240, 300, and 360 min after 
inhalation of the individual treatment. 
The response to each treatment was assessed by compar- 
ing the postbronchodilator FEV, with the baseline value. 
We examined three separate criteria to decide if a response 
was greater than that expected by a random variation of the 
measurement: (1) - a rise in FEV, of at least 15% from the 
baseline value; (2) - an absolute increase in FEV, of at least 
160 ml [to exclude errors due to the known coefficient of 
variation of spirometry (7)]; (3) -an increase in FEV, 
greater than both 15% of baseline and 200 ml. 
We calculated the correlation coefficient using the 
Pearson test to find to what degree the maximum increase 
in FEV, after salmeterol or salbutamol and the increase in 
FEV, 15 min after salbutamol varied together. P values 
were two-tailed. We also calculated the linear regression to 
find the line that best predicted the maximum increase in 
FEV, after salmeterol or salbutamol from the increase in 
FEV, 15 min after salbutamol. 
Results 
All 100 patients completed the 4-day study. There were 
no significant differences between the baseline spirometric 
values of the four treatment groups (P>O.O5). 
In total, 85 out of 100 patients showed an increase in 
FEV, greater than 15% of baseline after salbutamol and/or 
salmeterol, 76 showed an increase of FEV, of at least 
160 ml from basal value, and 67 showed an increase in 
FEV, greater than both 15% of baseline and 200 ml. 
Fifteen minutes after inhalation of salbutamol, 47 
patients showed an increase in FEV, greater than 15% of 
baseline, whereas 48 showed an increase of FEV, of at least 
160 ml from basal value and 33 showed an increase in FEV, 
greater than both 15% of baseline and 200 ml (Table 1). On 
the contrary, 69 patients showed an increase in FEV, 
greater than 15% of baseline, 65 showed an increase of 
FEV, of at least 160 ml from basal value and 60 showed an 
increase in FEV, greater than both 15% of baseline and 
200 ml as maximum increase over baseline usually 24 h 
after inhalation of salmeterol. We must emphasize that 27 
out of 53 patients considered irreversible 15 min after 
inhalation of salbutamol according to criterion 1 showed an 
increase in FEV, greater than 15% of baseline, 20 out of 52 
patients regarded as non-responders according to criterion 
2 showed an increase of FEV, of at least 160 ml from basal 
value, and 18 out of 67 patients considered irreversible 
according to criterion 3 manifested an increase in FEV, 
greater than both 15% of baseline and 200 ml, all had the 
maximum degree of bronchodilation usually l-2 h after 
salbutamol administration. The correlation coefficient 
between maximum percent increase after salmeterol and 
percent increase 15 min after salbutamol was 0.564 
(P<O.OOOl) and that between maximum percent increase 
after salbutamol and percent increase 15 min after salbuta- 
mol was 0.803 (P<O.OOOl) (Fig. l), whereas the correla- 
tion coefficient between maximum increase in ml after 
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FIG. 1. Correlation between the maximum increase in 
FEVl after 50 5g salmeterol (SLM) or 200 5g salbutamol 
(SBM) and the increase in FEV, 15 min after 200 5g sal- 
butamol inhalation and their linear regression (SLM: 
solid line; SBM: dotted line) in 100 patients with stable 
COPD. Responses are expressed as % increase from 
baseline. 
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FIG. 2. Correlation between the maximum increase in 
FEVl after 50 5g salmeterol (SLM) or 200 5g salbutamol 
(SBM) and the increase in FEV, 15 min after 200 5g sal- 
butamol inhalation and their linear regression (SLM: 
solid line; SBM: dotted line) in 100 patients with stable 
COPD. Responses are expressed as increase in ml from 
baseline. 
salmeterol and increase in ml 15 min after salbutamol was 
0.605 (P<O.OOOl) and that between maximum percent 
increase after salbutamol and increase in ml 15 min after 
salbutamol was 0.779 (PcO.0001) (Fig. 2). 
Forty out of 69 patients who achieved an increase in 
FEV, greater than 15% of baseline as the maximum degree 
of bronchodilation after salmeterol also showed an early 
reversibility to salbutamol when assessed according to 
criterion 1, whereas 29 patients showed a good reversibility 
to salmeterol but no early reversibility to salbutamol, and 
only seven patients manifested early reversibility to salbuta- 
mol but were non-responders to salmeterol (Table 2). 
Fifty-eight out of 85 patients who showed an increase in 
FEV, greater than 15% of baseline as the maximum degree 
of bronchodilation, exhibited this improvement after both 
salbutamol and salmeterol, 16 only after salbutamol and 11 
only after salmeterol. According to criterion 2, 43 out of 70 
patients showed both early reversibility after salbutamol 
and maximum bronchodilation after salmeterol, and 22 
patients improved only after salmeterol, whereas only five 
subjects presented early reversibility after salbutamol, but 
not maximum bronchodilation after salmeterol. Fifty-seven 
out of 76 patients who presented an increase in FEV, 
greater than 160 ml from baseline as the maximum degree 
of bronchodilation responded both to salmeterol and sal- 
butamol, 11 after salbutamol and eight only after sal- 
meterol. Thirty-one out of 62 patients manifested an 
increase in FEV, greater than both 15% of baseline and 
200 ml both 15 min after salbutamol and 24 h after sal- 
meterol, and 29 only after salmeterol, whereas two patients 
were considered responders only 15 min after salbutamol, 
but not after salmeterol. Forty-four out of 67 subjects who 
met criterion 3 at their maximum effect manifested an 
increase in FEV, greater than both 15% of baseline and 
200 ml after both salmeterol and salbutamol, 15 only after 
salbutamol and 8 only after salmeterol. 
Discussion 
Patients with COPD are often tested for reversibility by the 
acute inhalation of a &agonist. However, the classification 
of patients as reversible or irreversible probably leads to 
significant undertreatment of patients with COPD. In fact, 
the implication of having irreversible airflow obstruction is 
that therapy will not be useful. On the contrary, many 
patients will respond to therapy over a longer period of 
time or to therapy administered with a different agent. 
Thus, patients with irreversible COPD defined by acute 
improvement in FEV, do not have fixed airflows and may 
be able to benefit from bronchodilator therapy (8,9). Obvi- 
ously, this does not mean that bronchodilator reversibility 
tests are without value, but emphasizes the need for a better 
understanding of the useful information that they can give 
us such as the maximum degree of bronchodilation that the 
patient can achieve in the short-term rather than the 
response to a specific drug (10). 
In the present study we have chosen a ‘point prevalence’ 
(after 15 min) for salbutamol reversibility, and a ‘period 
prevalence’ (after 2-4 h) for salmeterol response as the 
primary outcome variables. This approach may be criti- 
cized because salbutamol may induce maximum broncho- 
dilation later than 15 min after its administration, but the 
criterion was preferred to reflect clinical practice. We high- 
light that recent British Thoracic Society guidelines for 
management of chronic obstructive pulmonary disease (11) 
state that spirometric values should be measured before 
and 15 min after an adequate dose of inhaled a-agonist 
when testing airflow reversibility. This is not the case of 
salmeterol because this long-acting &-agonist does not 
include a fast onset of action. 
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Our data clearly demonstrate that many patients suf- 
fering from stable COPD show a beneficial response 
to &adrenoceptor agonists with a positive correlation 
between degree of the maximum increase in FEV, after a 
short-acting agent or even inhalation of a long-acting one 
and the increase in FEV, 15 min after the inhalation of a 
short-acting &agonist. Another important finding is that 
patients who do not show early reversibility after a short- 
acting agent can still benefit from a short-acting &agonist 
or even a long-acting one because these drugs can often 
improve lung function in these subjects despite their 
classification as being irreversible. Our opinion is in line 
with that of Vollmer et al. (12) who observed that test effect 
(reversibility within 15 min after inhalation of 2OOpg sal- 
butamol) was significantly less than the best effects (maxi- 
mum 24-h effects) of 2OOpg salbutamol, 2OOpg fenoterol, 
and 5Opg salmeterol in 15 patients with chronic airflow 
obstruction. In any case, we can not exclude that the lack of 
correlation between early reversibility to salbutamol and 
maximum effect of salmeterol and/or salbutamol which we 
observed in several patients might reflect the poor repro- 
ducibility of reversibility tests in these patients and could 
possibly be that the variations of the response and not the 
different P-agonist could account for the changed response 
on different days. 
In conclusion, this study would suggest that the assess- 
ment of early reversibility should not be used as the basis 
for therapeutic decisions. Because of the imperfect relation- 
ship between the early bronchodilator response to salbuta- 
mol and the maximum response to salbutamol and 
salmeterol, we think that therapeutic decision on whether 
or not to prescribe a &agonist in patients with COPD 
should not be made on the salbutamol early reversibility 
test but should be based on the proven clinically significant 
effect of the drug in question. 
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